Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 2040-2041, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Croal, B. L.
Right arrow Articles by Loening, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Croal, B. L.
Right arrow Articles by Loening, S. A.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:2040-2041.)
© 1999 American Association for Clinical Chemistry, Inc.

Letters

Complexed Prostate-specific Antigen and the "Prostate-specific Antigen Gap"

Bernard L. Croal1,a, Ian Mitchell2, Arthur Dickie1, Patrica A. Duff1, Nicholas P. Cohen2 and Iain S. Ross1

Departments of
1 Clinical Biochemistry, and
2 Urology, Grampian University Hospitals Trust, Aberdeen AB25 2ZD, United Kingdom
a Author for correspondence. Fax 011-44-01224-694378; e-mail b.l.croal@abdn.ac.uk.


To the Editor:

Jung et al. (1) reported an apparent gap between total serum prostate-specific antigen (t-PSA) and the sum of free PSA (f-PSA) plus {alpha}1-antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH). The gap may be attributable to a variety of technical artifacts such as different recognition of multiple forms of f-PSA or t-PSA in the two groups of patients or the lack of equimolarity of the tests used (1). Of more interest, however, is the suggestion by the authors that the appearance of this "PSA gap" reflects an increase in minor PSA complexes in PCa patients that their assay for ACT-PSA does not detect. Indeed, they suggest that such an observation contradicts the high expectations (2. . . [Full Text of this Article]


References

Klaus Jung3,a

a Author for correspondence. Fax 49-30-2802-1402; e-mail klaus.jung@charite.de.

Brigitte Brux4
Pranav Sinha4
Michael Lein3
Dietmar Schnorr3
Stefan A. Loening3

Departments of
3 Urology and,
4 Laboratory Medicine, University Hospital Charité, Humboldt University Berlin, Schumannstrasse 20/21, D-10098 Berlin, Germany


To the Editor:


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.